What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call

Ultragenyx is cutting about 20% of its staff while ending drug programs for Angelman and Wilson diseases

Ultragenyx will eliminate about 250 jobs, end Angelman and Wilson disease programs, and reduce research spending while continuing launches of two approved gene therapies.

Ultragenyx (RARE) Q3 2026 Earnings Call Transcript

Workforce cuts and a $350 million voucher sale reshape its path to profit.

Ultragenyx cuts staff after another study fails

Today's biotech news includes whistleblower lawsuit filed against Madrigal Pharma, how a blue Congress could affect drugmakers, and more

What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call

Ultragenyx Pharmaceutical (NASDAQ:RARE) said its third quarter included two U.S. gene therapy approvals, a failed late-stage Angelman syndrome study, the termination of its Wilson disease program and restructuring actions intended to support GAAP profitability in 2027. Chief Executive Officer and P

Ultragenyx Sets 2027 Expense Targets as It Winds Down GTX-102

The company plans to reduce its workforce by about 20% and reaffirmed its forecast for full-year GAAP profitability in 2027.

Ultragenyx shrinks workforce and axes assets to halve R&D spend

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.